Phase 2 N=65 MK-3475 in Melanoma and NSCLC Patients With Brain Metastases
Melanoma · Non-Small Cell Lung Cancer · Brain Metastases
Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=22 Whole Brain Radiation Therapy With Boost to Metastatic Tumor Volume Using RapidArc
Neoplasm Metastasis
Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants
Phase 2 N=17 Carboplatin and Temozolomide (Temodar) for Recurrent and Symptomatic Residual Brain Metastases
Brain Tumor · Brain Metastases
Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response
N/A N=40 Stereotactic Radiation Therapy in Treating Patients With Brain Metastases
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients
N/A N=13 Managing Distress in Malignant Brain Cancer
Cancer Metastatic to Brain · Brain Metastases, Adult
Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale
N/A N=52 MRI Study of Changes in Blood-Brain/Tumor-Barrier Permeability in Patients With Brain Metastases During and After Radiotherapy
Brain Metastases
Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume
Phase 2 N=26 Temozolomide and Radiation Therapy in Treating Patients With Brain Metastasis Secondary to Non-Small Cell Lung Cancer
Lung Cancer · Metastatic Cancer
Primary: Number of Patients With Intracranial Response — 3 participants
Phase 2 N=24 TPI 287 in Breast Cancer Metastatic to the Brain
Breast Cancer
Primary: Overall Response Rate (ORR) — 21 Participants
N/A N=15 Advanced MRI Scan Before and After Radiation Therapy for the Detection of Intracranial Metastasis
Malignant Solid Neoplasm
Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05
Phase 2 N=58 GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain Metastases
Melanoma · Brain Metastases
Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year
Phase 2 N=8 Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Kidney Cancer · Melanoma (Skin) · Metastatic Cancer
Primary: Central Nervous System (CNS) Response Rate by RECIST Criteria — 3; 2 participants
Phase 3 N=213 Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases
Breast Cancer · Cognitive/Functional Effects · Lung Cancer
Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001
Phase 3 N=472 Oral HYCAMTIN Plus Whole Brain Radiation Therapy In Treatment Of Brain Metastases Resulting From Non-Small Lung Cancer
Lung Cancer, Non-Small Cell
Primary: Overall Survival — 4.0; 3.6 months — p=0.1862
N/A N=12 PET/CT Evaluation of Primary and Metastatic Brain Tumors With a Novel Radioiodinated Phospholipid Ether Analogue I-NM404
Glioblastoma Multiforme · Brain Metastases
Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV
Phase 2 N=41 Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Melanoma · Non-small Cell Lung Cancer · Brain Metastasis
Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants
Phase 2 N=49 Temozolomide and Vinorelbine in Treating Patients With Recurrent Brain Metastases
Metastatic Cancer
Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants
Phase 1 N=25 Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases
Metastatic Malignant Neoplasm in the Brain · Metastatic Melanoma · Mucosal Melanoma
Primary: Dose Limiting Toxicities — 0; 0; 0 Participants
Phase 2 N=51 Phase II Trial of Stereotactic Radiosurgery Boost Following Surgical Resection for Brain Metastases
Brain Metastasis · Bladder Cancer · Breast Cancer
Primary: Local Control — 13; 23; 2; 1 participants
N/A N=24 Pre-operative Stereotactic Radiosurgery Followed by Resection for Brain Metastases
Malignant Neoplasm Brain
Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients
Phase 2 N=10 STAR Cape+BKM120 MBC With Brain Met
Brain Metastases · Breast Cancer · Metastatic Breast Cancer
Primary: Clinical Benefit Rate (CBR) — 0.1 proportion of patients with CBR
Phase 2 N=27 Bevacizumab in Pats w/ Recurrent ST Brain Metas Who Have Failed Whole Brain Radiation Therapy
Metastatic Cancer · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants
Phase 2 N=59 Exploratory Study, Evaluating the Treatment Effect of Surgery Plus GLIADEL® Wafer in Patients With Metastatic Brain Cancer
Metastatic Brain Cancer
Primary: Rate of Deterioration in Neurocognitive Functioning (NF) at Month 12 — 2.8 percentage of participants
N/A N=24 Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
Metastatic Malignant Neoplasm to Brain · Unspecified Adult Solid Tumor, Protocol Specific
Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…
Phase 2 N=55 Whole Brain Radiotherapy With or Without Temozolomide at Daily Fixed-dose for Brain Metastases Treatment
Brain Neoplasms
Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019
Phase 3 N=151 Study to Establish the Diagnostic Performance of 18F Fluciclovine PET in Detecting Recurrent Brain Metastases
Brain Metastases
Primary: Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) Subject Level — 23.8; 34.1; 36.6; 82.6 percentage
N/A N=13 A Dose Escalation Trial of Five Fraction Stereotactic Radiation Therapy for Brain Metastases
Brain Metastases
Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy
Phase 2 N=48 Encorafenib and Binimetinib Before Local Treatment in Patients With BRAF Mutant Melanoma Metastatic to the Brain
Metastatic Melanoma · Brain Metastases
Primary: Intracranial Objective Response (iORR) by Modified RECIST 1.1 Before Local Radiotherapy Treatment in Full Dataset — 34; 13; 1; 20 Participants
N/A N=28 Brain Irradiation and Tremelimumab in Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Progression Free Survival (irPFS) — 21; 1; 3; 1 Participants
Phase 2 N=72 Evaluation of Tumor Response to Ipilimumab in the Treatment of Melanoma With Brain Metastases
Melanoma
Primary: Disease Control Rate by Modified World Health Organization (mWHO) Tumor Assessment Criteria — 17.6; 4.8; 23.5; 9.5 Percentage of participants
Phase 2 N=242 Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Neoplasms, Breast
Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants